Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus

PharmacoEconomics

Volumn 32, Issue 1, 2014, Pages 15-27

  Asche, Carl V ^a   Hippler, Stephen E ^b   Eurich, Dean T ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Illinois Neurological Institute Stroke Network   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C;

BODY WEIGHT; DISEASE CONTROL; DRUG SCREENING; EMBASE; HEALTH CARE UTILIZATION; HUMAN; LIFESPAN; MEDLINE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84898816345     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0117-7     Document Type: Review

References (29)

1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. (Pubitemid 46048557)
2. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36(Suppl 1):S11-66.
3. http://www.fda.gov/drugs/drugsafety/ucm343187.htm. Accessed 30 August 2013
4. Beaudet A, Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, Lloyd A. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011;14(3):357-66.
5. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med. 2012;23(2):126-31.
6. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010;33(4):695-700.
7. Lage MJ, Fabunmi R, Boye KS, Misurski DA. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther. 2009;26(2):217-29.
8. Tarride JE, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010;28(4):255-77.
9. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011;183(16):1213-20.
10. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab. 2008;10(Suppl 1):43-55.
11. Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol. 2008;7:24.
12. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med. 2012;29(3):313-20.
13. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin. 2011;27(5):897-906.
14. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011;33(11):1698-712.
15. Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, Dilla T. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinol Nutr. 2011;58(7):331-40.
16. Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes Metab. 2009;11(11):1068-79.
17. Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007;23(3):609-22. (Pubitemid 46456909)
18. Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther. 2011;14(1):65-73.
19. Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prime Care Diabetes. 2012;6(2):127-36.
20. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):623-30.
21. Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2009;47(8):501-15.
22. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. (Pubitemid 351831356)
23. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. (Pubitemid 351831357)
24. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54.
25. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26.
26. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest. 1992;102:270-3.
27. Adang E, Voordijk L, Jan van der Wilt G, Ament A. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy. 2005;74:146-56. (Pubitemid 41253718)
28. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-28. (Pubitemid 39390832)
29. Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. Low-value services in value-based insurance design. Am J Manag Care. 2010;16:280-6.